BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
GlobalData on MSN2d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of ...
Investor's Business Daily on MSN1d
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback